Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

7 Oct 2009 07:00

RNS Number : 3501A
Intercede Group PLC
07 October 2009
 



7 OCTOBER 2009

INTERCEDE GROUP plc

("Intercede" or "the Company")

Trading Update

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces excellent progress in the six months ended 30 September 2009.

Sales for the first half of the current financial year are more than 40% higher than for the comparable period last year. The Directors are also pleased to report that the Company has strongly increased its operating profit before exceptional items during the period.

The growth in sales is especially encouraging, because it is based both on existing customers expanding deployments installed in earlier periods and on new licence sales into new markets for actual end-customer projects. As a result, we are now experiencing a return on the investment made in development and sales efforts in previous years. Our expansion into new sectors and territories is also producing a fresh and immediate stream of revenue. This is evidence of the ongoing strength and viability of Intercede's business model and of a strategy that is being successfully executed. 

Key achievements during the period include:

Maintaining and expanding existing major projects for Lockheed MartinUK Government, US Federal Government, NHS and others. 

Winning new contracts to supply MyID to customers in AustraliaAustriaCzech RepublicRomaniaSlovakiaSwitzerland and the US.

Deploying MyID systems at a major security printing and smart card manufacturer, at a major Scandinavian bank and within a European government agency.

Adding the US Social Security Administration to Intercede's Federal HSPD-12 customer list. 

Further details will be provided when Intercede announces its Interim Results for the six months ended 30 September 2009, which is expected to take place in December 2009.

The reported period includes exceptional costs for defending a previously reported patent infringement case in the US filed by ActivIdentity Corporation. Intercede's answer and counterclaims deny that its products infringe ActivIdentity's patent and allege further that this patent is invalid and unenforceable. In addition, Intercede has filed counterclaims against ActivIdentity, including alleging violations of US antitrust law. The court recently rejected ActivIdentity's challenge to Intercede's antitrust claims and one basis for a declaration of unenforceability. While the court dismissed other counterclaims alleging fraudunfair competition, and an additional basis for a declaration of unenforceability, it gave Intercede the right to re-plead those claims with more factual detail. Intercede filed its amended counterclaims on 28 September 2009. Intercede intends to pursue its defence and its counterclaims vigorously. 

Costs and cash collections have also been kept under control throughout the period, as evidenced by a half year cash balance of £3,913,00, compared to £3,711,000 at 31 March 2009 and £1,839,000 at 30 September 2008. The cash position as at 30 September 2009 is thus more than double that of a year ago, notwithstanding the legal costs incurred to date in defending the patent infringement case brought by ActivIdentity and in pursuing the Company's counterclaims against ActivIdentity. 

Richard ParrisIntercede's Chairman and Chief Executive, said:

"Our order book indicates that Intercede is on track to continue our planned growth trajectory for this year and beyond. I am delighted that our sales pipeline is stronger than ever and that a number of our existing larger projects are set to exceed expectations in terms of future growth. In particular our entry into the national identity market is proving to be particularly rewarding while our partnerships with Lockheed Martin, Thales and VeriSign are making continuing and growing contributions to operating profit."

About Intercede 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management. Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. 

For more information visit http://www.intercede.com.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Charles Cunningham

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFSMFMMSUSEFS
Date   Source Headline
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.